Nomura Adjusts Joinn Laboratories' Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral

05:40 AM EDT, 04/30/2024 (MT Newswires) -- Nomura Adjusts Joinn Laboratories' Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral Price (RMB): ¥16.39, Change: ¥-1.82, Percent Change: -9.99%

MT NewswiresApr 30 05:40 ET

Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell by more than 11%, and the impact of experimental impairment increased the company's year-on-year change from profit to loss in the first quarter

Zhaoyan Pharmaceutical (06127) fell by more than 11%. As of press release, it was down 11.12% to HK$8.79, with a turnover of HK$14.2872 million.

Zhitong FinanceApr 29 21:48 ET

Zhaoyan Pharmaceutical (06127) lost 272 million yuan to mother in the first quarter

According to the Zhitong Finance App, Zhaoyan Pharmaceutical (06127) released its report for the first quarter of 2024. Operating revenue was 325 million yuan (RMB, same below), down 12.07% year on year; net loss attributable to shareholders of listed companies was 272 million yuan, profit of 188 million yuan for the same period last year; basic loss per share was 0.36 yuan.

Zhitong FinanceApr 29 07:12 ET

昭衍新藥：2024年度第一季度報告

Futu NewsApr 29 07:04 ET · Announcements

昭衍新藥：2023年度報告

Futu NewsApr 29 05:40 ET · Announcements

Zhaoyan New Pharmaceutical (06127): Wuxi Jinyifu New Biomedical Venture Capital Partnership (Limited Partnership) adds limited partner Xiangtang Heyi

Zhaoyan New Pharmaceutical (06127) was announced. On February 5, 2024, the board of directors reviewed and approved the “About...

Zhitong FinanceApr 19 05:10 ET